Creating the small-trade-area mega drugstore (1993)
A contrarian bet: a big box in a small trade area
The heart of this decision is that Uno turned a retail commonplace on its head — the rule that a large store belongs in a large trade area. Rather than fight over populous towns, he aimed at small trade areas where competitors were thin, and deliberately placed there a large store that carried even food. He funnelled the gross margin on drugs and cosmetics into cheap food, and dropped fresh produce to cut the handling and the labour. Not a drugstore, not a supermarket, not a convenience store, but a format that met all of those needs in a single shop — and Uno assembled it from a small provincial town. The twenty years of patience in Nobeoka can be read as the run-up to this one move.
The strength of having created the format itself did not thin as the company grew. Keep gross margins low but cut SG&A by more, and cheap prices and profit can coexist — this single design ran unbroken from one Kyushu store to ¥1 trillion in sales and some 1,600 outlets. The wholesale abolition of loyalty points in favour of everyday low prices, and the expansion of scale through self-built openings rather than M&A, can both be read as later choices made to defend this design. How to manufacture cheapness, and how to preserve that cheapness after scaling up — Cosmos’s course shows one company’s answer, one that placed the design of the store itself at the centre of competition.
Read the full dossier in Japanese →
The Japanese edition carries the complete record of this decision — the situation that forced it, the options weighed, what actually followed, and the sources behind every claim.
Other key decisions at Cosmos Pharmaceutical
Yen amounts are converted at the average rate of each figure’s own year — not today’s rate; the revenue chart is shown in yen. Exchange rates & sources — the full ¥/US$ table →
Disclaimer
- This page is provided for general information only and is not investment advice, nor a recommendation to buy or sell any security.
- Figures are compiled independently and include our own estimates, approximations and machine-processed data; we make no warranty as to their accuracy or completeness.
- Sources are primarily each company’s securities reports and other public filings, but errors and omissions may remain.
- Any use of this information is at the reader’s own risk. Past performance does not indicate future results.
- Company names, logos and other marks belong to their respective owners.
Data API
Cosmos Pharmaceutical’s history, financials, executives and
shareholders are published as static JSON — no key, plain GET.
Full specification →
| Method | Endpoint | Returns |
|---|---|---|
| GET | /api/companies.json | All companies |
| GET | /api/3349/manifest.json | Resource index |
| GET | /api/3349/history.json | History overview |
| GET | /api/3349/timeline.json | Chronology |
| GET | /api/decisions.json | All management decisions (index) |
| GET | /api/3349/decisions.json | Management decisions (index) |
| GET | /api/3349/decisions/{slug}.json | One decision (full dossier) |
| GET | /api/3349/executives.json | Executives |
| GET | /api/3349/shareholders.json | Major shareholders |
| GET | /api/3349/financials.json | Financial statements |
| GET | /api/3349/financials-longterm.json | Long-term results |
| GET | /api/3349/segments.json | Business segments |
| GET | /api/3349/regions.json | Sales by region |
| GET | /api/3349/workforce.json | Workforce |